Literature DB >> 26293922

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.

Pengda Liu1, Wenjian Gan1, Y Rebecca Chin1, Kohei Ogura1, Jianping Guo1, Jinfang Zhang1, Bin Wang1, John Blenis2, Lewis C Cantley2, Alex Toker1, Bing Su3, Wenyi Wei4.   

Abstract

UNLABELLED: mTOR serves as a central regulator of cell growth and metabolism by forming two distinct complexes, mTORC1 and mTORC2. Although mechanisms of mTORC1 activation by growth factors and amino acids have been extensively studied, the upstream regulatory mechanisms leading to mTORC2 activation remain largely elusive. Here, we report that the pleckstrin homology (PH) domain of SIN1, an essential and unique component of mTORC2, interacts with the mTOR kinase domain to suppress mTOR activity. More importantly, PtdIns(3,4,5)P3, but not other PtdInsPn species, interacts with SIN1-PH to release its inhibition on the mTOR kinase domain, thereby triggering mTORC2 activation. Mutating critical SIN1 residues that mediate PtdIns(3,4,5)P3 interaction inactivates mTORC2, whereas mTORC2 activity is pathologically increased by patient-derived mutations in the SIN1-PH domain, promoting cell growth and tumor formation. Together, our study unravels a PI3K-dependent mechanism for mTORC2 activation, allowing mTORC2 to activate AKT in a manner that is regulated temporally and spatially by PtdIns(3,4,5)P3. SIGNIFICANCE: The SIN1-PH domain interacts with the mTOR kinase domain to suppress mTOR activity, and PtdIns(3,4,5)P3 binds the SIN1-PH domain to release its inhibition on the mTOR kinase domain, leading to mTORC2 activation. Cancer patient-derived SIN1-PH domain mutations gain oncogenicity by loss of suppressing mTOR activity as a means to facilitate tumorigenesis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26293922      PMCID: PMC4631654          DOI: 10.1158/2159-8290.CD-15-0460

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  51 in total

1.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

2.  Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation.

Authors:  A D Kohn; F Takeuchi; R A Roth
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

3.  The human stress-activated protein kinase-interacting 1 gene encodes JNK-binding proteins.

Authors:  Wayne Schroder; Gillian Bushell; Tom Sculley
Journal:  Cell Signal       Date:  2004-12-15       Impact factor: 4.315

4.  Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.

Authors:  T F Franke; D R Kaplan; L C Cantley; A Toker
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

5.  Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

Authors:  Li Ma; Zhenbang Chen; Hediye Erdjument-Bromage; Paul Tempst; Pier Paolo Pandolfi
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

6.  Mip1, an MEKK2-interacting protein, controls MEKK2 dimerization and activation.

Authors:  Jinke Cheng; Dongyu Zhang; Kihwan Kim; Yingxin Zhao; Yingming Zhao; Bing Su
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 7.  Dysregulation of the TSC-mTOR pathway in human disease.

Authors:  Ken Inoki; Michael N Corradetti; Kun-Liang Guan
Journal:  Nat Genet       Date:  2005-01       Impact factor: 38.330

8.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

9.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

10.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

View more
  142 in total

Review 1.  mTOR signaling in stem and progenitor cells.

Authors:  Delong Meng; Anderson R Frank; Jenna L Jewell
Journal:  Development       Date:  2018-01-08       Impact factor: 6.868

2.  c-Jun N-terminal kinase (JNK)-mediated induction of mSin1 expression and mTORC2 activation in mesenchymal cells during fibrosis.

Authors:  Natalie M Walker; Serina M Mazzoni; Ragini Vittal; Diane C Fingar; Vibha N Lama
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

3.  Tyrosines-740/751 of PDGFRβ contribute to the activation of Akt/Hif1α/TGFβ nexus to drive high glucose-induced glomerular mesangial cell hypertrophy.

Authors:  Falguni Das; Nandini Ghosh-Choudhury; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Cell Signal       Date:  2017-09-23       Impact factor: 4.315

Review 4.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

5.  Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt.

Authors:  Catherine E Gleason; Juan A Oses-Prieto; Kathy H Li; Bidisha Saha; Gavin Situ; Alma L Burlingame; David Pearce
Journal:  J Cell Sci       Date:  2019-04-09       Impact factor: 5.285

Review 6.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

7.  Genetic Predisposition to Glioma Mediated by a MAPKAP1 Enhancer Variant.

Authors:  Liming Huang; Wenshen Xu; Danfang Yan; Xin You; Xi Shi; Shu Zhang; Hualan Hong; Lian Dai
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

8.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

9.  mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Authors:  Thanh-Trang T Vo; J Scott Lee; Duc Nguyen; Brandon Lui; William Pandori; Andrew Khaw; Sharmila Mallya; Mengrou Lu; Markus Müschen; Marina Konopleva; David A Fruman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

Review 10.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.